Back to Search
Start Over
Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine 1 H-MR spectroscopy study
- Source :
- Neurobiology of aging
- Publication Year :
- 2020
-
Abstract
- It is unclear whether alterations in cerebral pH underlie Alzheimer's disease (AD) and other dementias. We performed proton spectroscopy after oral administration of histidine in healthy young and elderly persons and in patients with mild cognitive impairment and dementia (total N = 147). We measured cerebral tissue pH and ratios of common brain metabolites in relation to phosphocreatine and creatine (Cr) in spectra acquired from the hippocampus, the white matter (WM) of the centrum semiovale, and the cerebellum. Hippocampal pH was inversely associated with age in healthy participants but did not differ between patients and controls. WM pH was low in AD and, to a lesser extent, mild cognitive impairment but not in frontotemporal dementia spectrum disorders and pure vascular dementia. Furthermore, WM pH provided incremental diagnostic value in addition to N-acetylaspartate to Cr ratio. Our study suggests that in vivo assessment of pH may be a useful marker for the differentiation between AD and other types of dementia.
- Subjects :
- 0301 basic medicine
In vivo magnetic resonance spectroscopy
Aging
medicine.medical_specialty
Creatine
Phosphocreatine
White matter
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Centrum semiovale
medicine
Dementia
Vascular dementia
business.industry
General Neuroscience
medicine.disease
030104 developmental biology
Endocrinology
medicine.anatomical_structure
chemistry
Neurology (clinical)
Geriatrics and Gerontology
business
030217 neurology & neurosurgery
Developmental Biology
Frontotemporal dementia
Subjects
Details
- ISSN :
- 01974580
- Database :
- OpenAIRE
- Journal :
- Neurobiology of aging
- Accession number :
- edsair.doi.dedup.....fd4e6297cf164dc63fbcb96180df3c7a
- Full Text :
- https://doi.org/10.1016/j.neurobiolaging.2019.11.012